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The focal adhesion kinase (FAK) and the related protein-tyrosine kinase 2-beta (Pyk2) are highly versatile
multidomain scaffolds central to cell adhesion, migration, and survival. Due to their key role in cancer
metastasis, understanding and inhibiting their functions are important for the development of targeted
therapy. Because FAK and Pyk2 are involved in many different cellular functions, designing drugs with
partial and function-speciﬁc inhibitory effects would be desirable. Here, we summarise recent progress
in understanding the structural mechanism of how the tug-of-war between intramolecular and inter-
molecular interactions allows these protein ‘nanomachines’ to become activated in a site-speciﬁc
manner.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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promising drug targets
Flexible multidomain proteins are key players in eukaryotic sig-
nalling networks. In response to the presence of ligands, post-
translational modiﬁcations or subcellular conditions, these mole-
cules adopt differently ‘assembled’ or ‘open’ conformations, which
produce different functions (Vogel et al., 2004). Multidomain pro-
teins are thus versatile nanomachines and their intra- and inter-
molecular interactions are promising targets for inhibitors of
protein:protein interactions (Falchi et al., 2014; Zhang et al., 2014).
Given the correlation between structure and function, determining
the 3D structures of multidomain proteins and their ligand com-
plexes is important for understanding their different biological roles,
and for rationally designing protein-protein interaction inhibitors
(PPIIs) againstparticular subsets of functions.However,multidomain
proteins are often too ﬂexible for X-ray crystallography, too large for
nuclear magnetic resonance (NMR) and too small for electron mi-
croscopy (EM). Obtaining 3D structural information on these mole-
cules consequently requires hybrid approaches, where partial high-
resolution information (from X-ray crystallography or NMR) is
combinedwith low-resolution information [for example fromsmall-
angle X-ray scattering (SAXS), EM or atomic force microscopy),
computational methods (molecular modelling, molecular dynamics
simulations) and distance constraints coming from experimental
methods [such as F€orster resonance energy transfer (FRET), chemical
cross-linking, mutation or binding studies]. For recent reviews, see
(Adams et al., 2013; Graewert and Svergun, 2013; Kovacs et al., 2015;
Lasker et al., 2012;RamboandTainer, 2013;Rozycki andBoura, 2014).
Herein we summarise recent advances in our understanding of
the structure-function relationship of the non-receptor tyrosine
kinase FAK and its close homologue Pyk2. Following the editor's
recommendation, this review is based on an oral presentation
given at the 2014 EMBO workshop, ‘Advances in proteineprotein
analysis and modulation’, and thereby concentrates on how ligands
activate kinase-dependent functions of FAK at focal adhesions
(FAs). This concept introduces a certain bias, which we have tried to
minimise where possible. We also brieﬂy discuss how this mech-
anistic framework helps us to understand kinase-independent FAK
functions in other environments and how it may support calcium-
sensing by Pyk2.2. Multiple cellular functions of FAK
FAK is essential in embryonic development and wound healing
(see (Arold, 2011;Hall et al., 2011; Schaller, 2010)). In adult tissue, FAK
isexpressedonlyat lowlevels.However, FAK isoverexpressed inmost
cancers, and it endows cancer cells with functions that normal adult
tissue cells do not have, such as the capacity to survive following
detachment from the supporting structure. In so doing, FAK becomes
a key player in cancer cell metastasis and tissue invasion (Fu et al.,
2012; Sulzmaier et al., 2014; Zhang and Hochwald, 2014).
As indicated by its name, FAK is a central player for the assembly
and disassembly of FAs (Arold, 2011; Hall et al., 2011; Mitra et al.,
2005; Schaller, 2010). FAs are large and dynamic macromolecular
assemblies through which the actin cytoskeleton is connected tothe extracellular matrix (ECM). In addition to anchoring the cell,
FAs encode the state of the ECM into intracellular biochemical
pathways that control cell morphology, migration, differentiation,
proliferation, and survival (Gumbiner, 1996; Ridley et al., 2003;
Wehrle-Haller and Imhof, 2002). FAK is recruited to FAs in
response to integrin-mediated cell adhesion. However, FAK is also
involved in signalling of other cell surface receptors (including G
protein-coupled receptors, the Tcell receptor, the deleted-in-colon-
cancer netrin receptor and transmembrane tyrosine kinases) and is
acting in many cellular environments, such as lamellipodia, mi-
crotubules and the nucleus (Chapman and Houtman, 2014;
Schaller, 2010; Zhao and Guan, 2009). FAK can promote different
effects in the same subcellular localisation (such as assembly and
disassembly of FAs); it can also produce convergent effects at
different subcellular localisations (such as cancer cell invasion and
metastasis in lamellipodia or the nucleus) (Arold, 2011; Cance and
Golubovskaya, 2008; Hall et al., 2011; Schaller, 2010). This func-
tional versatility raises the question of how FAK achieves site-
speciﬁc and cell stateespeciﬁc functions.
FAK consists of a central kinase domain, ﬂanked by two non-
catalytic domains, the band 4.1, ezrin, radixin, moesin (FERM)
domain and the focal adhesion targeting (FAT) domain. These do-
mains are separated by long linkers of about 50 (FERM-kinase) and
220 (kinase-FAT) residues (Fig. 1). More than 50 ligands have been
reported for FAK, and each domain and linker region has its own set
of ligands. Some ligands bind to FAK in the nucleus, and others in
the cytoplasm (Fig. 1; red and black, respectively). A subset of
cytoplasmic ligands (green) is incompatible with or counteracts
autophosphorylation of FAK tyrosine 397.
The major role of the FAK kinase domain appears to be the
autophosphorylation of FAK Y397 (Ciccimaro et al., 2006). Y397 is
situated in the FERM-kinase linker, adjacent to a proline-rich motif
(PR1), and autophosphorylation of Y397 has to proceed in trans in
the full-length standard form of FAK (Brami-Cherrier et al., 2014;
Toutant et al., 2002). Once phosphorylated, this region constitutes
a bi-dentate binding site for the Src-homology 2 (SH2) and SH3
domains of Src family kinases Fyn and Src (which bind to pY397 and
PR1, respectively) (Arold et al., 2001; Schaller et al., 1994; Thomas
et al., 1998) (Fig. 1). The interaction with FAK activates these Src-
family kinases, which then provide most kinase activity associ-
ated with FAK, including phosphorylation of tyrosines within FAK
(including Y576/Y577 in the kinase activation loop, Y861 in the
kinase-FAT linker, and Y925 in the FAT domain) (Schaller et al.,
1999, 1994; Schlaepfer et al., 1994; Xie et al., 2008). Thus, auto-
phosphorylation of Y397 triggers the kinase-dependent functions
of the Src:FAK complex. In the absence of Y397 autophosphor-
ylation, FAK binds to different ligands and performs different
functions (Corsi et al., 2009). Hence FAK can be seen as a scaffolding
protein with a Y397-phosphorylation switch between different
conformational and functional states (Fig. 1).3. New insights into the structure and regulation of
individual FAK domains
The atomic-resolution 3D structures of the individual domains
of FAK have been previously described [(Fig. 2); for a detailed
Fig. 1. FAK is a multidomain scaffolding protein with many cellular ligands. Proteins associating with FAK in the nucleus are shown in red. Cytoplasmic ligands incompatible with, or
counteracting phosphorylation of Y397 are in green and other ligands in black. For references please see (Alam et al., 2014; Arold, 2011; Bongiorno-Borbone et al., 2005; Chen et al.,
2001; Fujita et al., 1998; Garces et al., 2006; Hall et al., 2011; Ho et al., 2012; Nagano et al., 2010; Oh et al., 2009; Plaza-Menacho et al., 2011; Tanaka et al., 2010; Wang et al., 2014).
PR: proline-rich region; SH: Src homology; FERM: band 4.1, ezrin, radixin, merlin; FAT: focal adhesion targeting. The colour code for the FERM, kinase and FAT domain is used for all
illustrations.
Fig. 2. The structure and functional motifs of individual FAK domains. Dashed lines indicate loops not included in the crystallographic structural model. Key regions and residues
discussed in the text are highlighted. (A) Crystal structure of FERM-kinase domain fragment (31-686) in the ‘closed’ autoinhibited conformation (PDB accession number 2J0J). (B)
Isolated FAT domain (purple) predominantly forms a four-helix bundle structure (PDB ID 3S9O). The S910PPP motif binds to site 1/4 located between helices H1 and H4. (C) FAT binds
two paxillin LD motifs (yellow helices) on two sites, site 1/4 (located between helices 1 and 4) and site 2/3 (located between H2 and H3); PDB ID 1OW7. (D) FAT domain showing
opening of H1 (PDB ID 1K04).
K.W. Walkiewicz et al. / Progress in Biophysics and Molecular Biology 119 (2015) 60e7162review, see (Alam et al., 2014; Arold, 2011; Hall et al., 2011)]. The
FAK FERM domain is composed of three lobes (F1eF3) and is
structurally similar to the FERM domains of those proteins after
which it was named (band 4.1, ezrin, radixin and moesin)
(Ceccarelli et al., 2006; Girault et al., 1999). However, the FAK FERMdomain has adapted this scaffold to engage different interactions
(such as binding to transmembrane receptor tails, or intra-
molecular interactions), or to engage in the same type of in-
teractions differently (for example binding to phospholipid head
groups) (Arold, 2011; Ceccarelli et al., 2006; Hall et al., 2011). The
K.W. Walkiewicz et al. / Progress in Biophysics and Molecular Biology 119 (2015) 60e71 63crystal structure of a FAK fragment comprising the FERM and kinase
domains (residues 31-686) revealed that the FERM domain can
dock onto the kinase domain (Fig. 2) (Lietha et al., 2007). This
assembled FERM-kinase conformation is stabilised by binding of
ATP to the kinase domain, yet is incompatiblewith phosphorylation
of Y576/Y577 in the kinase activation loop (Goni et al., 2014; Lietha
et al., 2007; Zhou et al., 2015). The FAK kinase domain cannot
efﬁciently autophosphorylate its activation loop tyrosines Y576/
Y577, but requires Src kinases for this modiﬁcation (Ciccimaro et al.,
2006). Binding of the Src kinase SH2 domain to pY397 requires
dissociation of the contacts between pY397 and the FERM F1 lobe
(Fig. 2A and data not shown), suggesting that this event weakens
the FERM:kinase interaction. Hence Y397 autophosphorylation,
which leads to phosphorylation of Y576/Y577 by Src kinases, ulti-
mately promotes an open, disassembled FAK conformation, as
experimentally observed using FRET sensors (Cai et al., 2008; Goni
et al., 2014; Lietha et al., 2007). Thus, the presence of ATP (which is
expected to be constitutive, given the high ATP concentrations in
the cell) and phosphorylation of the kinase activation loop stabilise
structurally and functionally distinct structural states.
Despite forming a simple four-helix bundle structure, the ~140
residue FAT domain also possesses several layers of regulation,
linked to conformational plasticity (Fig. 2B) (Alam et al., 2014; Arold
et al., 2002; Dixon et al., 2004; Hayashi et al., 2002; Kadare et al.,
2015; Prutzman et al., 2004). The interaction between FAT and
paxillin LD motifs results in FAK being recruited to FAs (Fig. 2C)
(Brown et al., 1996). FAT binds two helical LD motifs, one between
helices H1 and H4 (site 1/4), the other one between helices H2 and
H3 (site 2/3) (Bertolucci et al., 2005; Gao et al., 2004; Hoellerer
et al., 2003), whereas FAT-homology domains (FAHs) of other FA-
localising proteins (CCM3, GIT1/2 and vinculin) bind only one LD
motif (Alam et al., 2014; Brown et al., 1996; Li et al., 2011;
Schmalzigaug et al., 2007; Turner et al., 1990; Zhang et al., 2008).
FAT binds also two CD4 endocytosis motifs, in a structurally similar
way to LD motifs, allowing CD4 to recruit FAK for T cell receptor
signalling (Garron et al., 2008). Conversely, the FAT helix 4 is suf-
ﬁcient to bind to the talin FERM F3 lobe, and the FAT four-helix
bundle structure is not required for this interaction (Hayashi
et al., 2002; Lawson et al., 2012).
Phosphorylation and subsequent interaction of Y925 [located on
helix 1 (H1) of FAT] with the Grb2 SH2 domain requires opening of
H1 (Arold et al., 2002; Schlaepfer et al., 1994). H1-opening is pro-
moted by the P944XPP motif between H1 and H2 (Fig. 2B and D),
which functions as a molecular spring (Arold et al., 2002; KadareFig. 3. Similarities in the molecular architecture of FAK and Pyk2 homodimeric structures. (
crystallography (Brami-Cherrier et al., 2014). The dimeric FERM-kinase fragment was taken
FAT domains, were placed using SAXS (ab inito SAXS model is shown as grey surface) (B
positioning of FAT and linker residues (not shown). W266 (blue) is required for dimer for
conformation (Brami-Cherrier et al., 2014). (B) The Pyk2 FERM dimer found in the crystal la
where Pyk2 W273 (blue) at the dimer interface corresponds to FAK W266.et al., 2015). Despite being only a low-probability event in vitro
(Arold et al., 2002; Zhou et al., 2006), H1-opening is required in
cells for a subset of FAK functions, including phosphorylation of
Y925 and FA turnover (Kadare et al., 2015). However, H1-opening is
incompatible with FAT binding to paxillin LD motifs (Kadare et al.,
2015). In crystal structures of apo-FAT, the S910PPPmotif, situated in
an N-terminal extension of FAT, binds to site 1/4 (Arold et al., 2002;
Kadare et al., 2015) (Fig. 2B). This interaction is incompatible with
both FAT H1 opening and binding of LD motifs to site 1/4 (Hoellerer
et al., 2003; Kadare et al., 2015). The S910PPP motif, when phos-
phorylated by Erk 1/2 on serine 910, becomes a substrate for the
peptidyl-prolyl cis/trans isomerase PIN1. PIN1 recruits the protein
tyrosine phosphatase PTP-PEST, which dephosphorylates FAK Y397,
leading to increased FA turnover and tumour cell invasiveness
(Zheng et al., 2009, 2011). The structural and mechanistic effects of
S910 phosphorylation and cis/trans isomerisation remain unknown.
However, given the proximity of S910 to K1032 (located on FAT H4),
we speculate that phosphorylation reinforces the interaction of the
pS910PPP motif with the FAT domain core (Fig. 2B). Possible out-
comes of S910 phosphorylationmight include, but not be limited to,
competition with the LD motif bound to FAT helices 1/4, or stabi-
lisation of the 4-helix bundle structure of FAT.
Recent structural insights now provide a framework to under-
stand how different regulatory mechanisms combine to allow site-
speciﬁc conformations and functions.
4. Structural insight into full-length FAK
Since full-length FAK does not form crystals suitable for X-ray
analysis, we have used SAXS to obtain structural insights (Brami-
Cherrier et al., 2014). The ab initio low-resolution shape that we
obtained suggested that FAK forms dimers under our experimental
conditions. Fitting of this shape by the known atomic-resolution
fragments was enabled by our observation that all crystal struc-
tures that contained the FERM domain [including human (Brami-
Cherrier et al., 2014) and avian FERM (Ceccarelli et al., 2006) and
avian FERM-kinase fragments (Lietha et al., 2007)] contained the
same FERM:FERM dimer in the crystal lattice. These dimeric FERM-
kinase structures ﬁtted the full-length SAXS ab initio shape very
well and were used in conjunction with SAXS data on full-length
FAK to investigate the position of the missing residues located C-
terminal to the kinase domain. Although the low resolution pre-
cluded a precise positioning of the FAT domain, SAXS data sup-
ported that FATattached to the F2 lobe of the FERM domain (Brami-A) The model of dimeric full length FAK was established by combining SAXS and X-ray
from the crystal lattice of PDB 2J0J. The residues outside of this fragment, including the
rami-Cherrier et al., 2014). Note that the low resolution of SAXS precludes a precise
mation in vitro and in cells. FAT:FERM interactions additionally stabilise the dimeric
ttice of the Pyk2 FERM crystal structure (4EKU) corresponds to the FAK FERM dimers,
K.W. Walkiewicz et al. / Progress in Biophysics and Molecular Biology 119 (2015) 60e7164Cherrier et al., 2014).
5. Functional implications of FAK dimerisation through the
FERM domain
This full-length model suggested that FAK can be dimeric
(Fig. 3A), and that this dimer conformation requires a FERM:FERM
interaction, centred on an interface formed by W266 (Brami-
Cherrier et al., 2014). FAK dimerisation was not anticipated, since
none of the FAK fragments (FERM, kinase, FERM-kinase or FAT)
formed stable dimers in solution (with the exception of the arm-
exchanged FAT dimers, which occur in vitro under high FAT con-
centrations, and are unlikely to play a major role in cells) (Arold
et al., 2002; Kadare et al., 2015; Lietha et al., 2007). However,
FAK self-association is apparent in vitro and in cells and requires
intact W266 (Brami-Cherrier et al., 2014). Moreover FAK transient
dimerisation is needed for autophosphorylation of Y397 in vitro
and in cells (Brami-Cherrier et al., 2014; Toutant et al., 2002). In
this regard, full-length FAK behaves differently from the FERM-
kinase fragment, which can autophosphorylate Y397 in cis
(Lietha et al., 2007). Given the length of the FERM-kinase linker,
and position of Y397 within this linker, transient dissociation of
the FERM:kinase interaction is required for phosphorylation of
Y397 in trans across the W266-mediated dimer. The apparent
in vitro dimerisation dissociation constant (Kd) for the isolated
FERM domain is only ~30 mM, which explains why this interaction
has gone unnoticed in previous experiments and why it is only
apparent in the highly concentrated FERM domains within crystal
structures (Brami-Cherrier et al., 2014). From our data we esti-
mated the apparent dimerisation Kd of full-length FAK to be
150 nM, whereas the FAK concentration in cells is only about
10 nM (Brami-Cherrier et al., 2014). These ﬁndings suggested that
trans-autophosphorylation of FAK Y397, and hence activation of
kinase-dependent functions, requires local enrichment and clus-
tering of FAK. Indeed, using acceptor photobleaching and confocal
microscopy, we showed that FAK self-associates and autophos-
phorylates speciﬁcally at FAs, suggesting that FAK reaches the
required local concentration speciﬁcally and exclusively at these
structures. Moreover, our data also suggested that the weak
FERM:FERM dimer needs to be stabilised by additional interactions
from the region that is C-terminal to the kinase domain (Brami-
Cherrier et al., 2014).
6. FERM and FAT synergise to stabilise FAK dimerisation
The full-length structural data also suggested that the FERM
domain binds to the FAT domain. We conﬁrmed this interaction
experimentally, establishing a Kd of 600 nM for recombinant FAT
and FERM domains. The observation that the presence of a 10-fold
excess of free FAT reduced substantially the amount of dimeric FAK
suggested that the FERM:FAT interaction stabilises FAK dimers by
occurring in trans (Brami-Cherrier et al., 2014), which is compatible
with the length of the kinase-FAT linker. Counterintuitively, the
presence of paxillin LD4 peptides enhances the association be-
tween FAT and FERM. Deletion of the N-terminal extension of FAT
(residues 895 to 915) decreased the binding of FAT to FERM, but the
presence of LD4 peptides restored the interaction of the N-termi-
nally deleted FAT (Brami-Cherrier et al., 2014). The exact region of
FAT that binds to FERM is unknown, as is the mechanism by which
LD4 increases this interaction.
7. The multifunctional basic motif of the FERM domain
The binding of FERM to FAT requires the K216AKTRLK basic
motif located in the FERM F2 lobe (Fig. 3A), but the exact site ofinteraction remains to be determined (Brami-Cherrier et al.,
2014). Biosensor studies in live cells and cell-free assays have
shown that the same basic motif is required for binding of
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] and that this
interaction correlates with disassembly of the inhibitory FERM:-
kinase interactions and triggers autophosphorylation of Tyr397
(Cai et al., 2008; Papusheva et al., 2009). Although the exact mode
of PI(4,5)P2 binding is unknown, all-atom molecular dynamics
simulations suggested an allosteric link between binding of
PI(4,5)P2 to FERM F2 and the FERM F1 lobe (Zhou et al., 2015).
Work by Goni et al. shows that both the charged head group and
the fatty acid chain of PI(4,5)P2 are needed to induce clustering
and partial structural opening of the inhibitory FERM:kinase as-
sociation, which then stimulates Y397 autophosphorylation (Goni
et al., 2014). Based on computational simulations, ﬂuorescence
measurements and crystallographic analysis of the FERM
K216AKTRLK->AAATALK mutant, the authors proposed a model in
which PI(4,5)P2 binding renders the FERM F2 lobe, and hence the
association of the F2 lobe with the C-terminal lobe of the kinase
domain, more ﬂexible (Goni et al., 2014). Rather than increasing
the propensity of the kinase domain to dissociate from FERM to
trans-autophoshorylate Y397 (as required within the W266-
mediated FAK dimer), the authors suggested that this increased
ﬂexibility leads to dissociation of the link between the FERM F1
lobe and the N-terminal kinase lobe, while maintaining the
connection between the kinase and the F2 lobe. To explain how a
FERM-bound kinase can nonetheless phosphorylate Y397 in trans,
the authors proposed that within PI(4,5)P2-induced clusters, FAK
molecules arrange themselves to allow their kinase domains to
phosphorylate Y397 of the FERM-kinase linker from their neigh-
bouring FAK molecule. Because we found that W266-mediated
FERM:FERM dimers are required for Y397 autophosphorylation
in cells and in cell-free assays in the absence of PI(4,5)P2 (Brami-
Cherrier et al., 2014), the lateral Y397 trans-phosphorylation
without FERM:kinase dissociation proposed by Go~ni et al. might
be an alternative and possibly synergistic route in clustered FAK
populations. In both models, the FERM:kinase interaction is
weakened by Src binding to pY397, and disrupted by subsequent
Src phosphorylation of the FAK kinase activation loop tyrosines
Y576/Y577.
Indeed, K216AKTRLK-dependent binding of FAK appears to be a
more general mechanism of ligand-induced coactivation. This
mode of action has been reported for two receptor tyrosine kinases
that can activate FAK, namely the phosphorylated hepatocyte
growth factor receptor (pc-Met) (Chen and Chen, 2006; Chen et al.,
2011) and rearranged during transfection (RET) (Plaza-Menacho
et al., 2011). It is possible that the doubly phosphorylated pc-Met
promotes FAK autophosphorylation using a charge-based mecha-
nism reminiscent of the one used by doubly phosphorylated lipid
head groups (Goni et al., 2014). The mechanism used by RET ap-
pears to be different, because the RET:FERM interaction (which
leads to phosphorylation of FAK Y576/577 by RET) is disrupted by
FAK-mediated RET phosphorylation, rather than promoted through
phosphorylation as observed for c-Met and lipid head groups
(Plaza-Menacho et al., 2011). How all these, and perhaps other, co-
activators compete or synergise with each other and with the
FERM-bound FAT domain is currently unclear and awaits further
structural and functional analysis.
Intriguingly, in addition to enabling activation of FAK kinase-
dependent functions at the plasma membrane, this basic
K216AKTRLK motif is also part of a nuclear localisation signal (NLS),
and mutation of K216 and K218 into alanine blocked nuclear
accumulation (Lim et al., 2008). Consequently, the interaction of
FAT with the FERM K216AKTRLK motif is expected to have an
important role in localisation and activation of FAK.
Fig. 4. Schematic model illustrating site-speciﬁc functions of FAK. FERM, kinase and FAT colours are as in Fig. 1. Flexible linker regions are in black. Ligands are not drawn to scale.
Phosphorylated residues are indicated by a P on a coloured circle, where red denotes Y397 and orange is used for other tyrosine residues. Serine phosphorylation events are not
included. The FERM:FAT interaction in dimeric FAK is shown in trans (see Section 6), however mechanisms in which a FERM:FAT interaction in cis stabilises FAK dimers cannot be
ruled out. At FAs, functionally important clustering of FAK molecules occurs. These clusters were not drawn for reasons of clarity. Trans-autophosphorylation of Y397 at FAs is shown
to imply transient FERM:kinase dissociation across the W266-meditated dimer. Please note that autophosphorylation following PIP2-induced clustering was suggested to proceed
without FERM:kinase dissociation (Goni et al., 2014). Phosphorylation of Y925 and subsequent recruitment of Grb2 is incompatible with the interaction of FAT with paxillin. In
mature FAs, other mechanisms can still attach FAK to focal adhesions, such as an interaction with talin, which does not need an assembled 4-helix bundle (Chen et al., 1995; Hayashi
et al., 2002; Lawson et al., 2012). However interaction with Grb2 correlates with mechanisms leading to FA dissociation (Ezratty et al., 2005). Please refer to Sections 6 and 9.1e9.3.
for a detailed description.
K.W. Walkiewicz et al. / Progress in Biophysics and Molecular Biology 119 (2015) 60e71 658. pH dependent activation
The FERM domain also harbours another trigger for auto-
activation. In a recent study, Ritt et al. presented direct evidence
linking FAK activation to changes in physiological pH in living cells
(Ritt et al., 2013). Cancer cells are known to have a higher intra-
cellular pH than normal cells, which is linked to cell migration and
cell proliferation, all of which are processes affected by FAK acti-
vation. Decreasing intracellular pH enhances the FERM-kinase
interaction and hence results in decreases in both Y397 phos-
phorylation and kinase activity as evident from FRET sensorebased
assays (Ritt et al., 2013). As a result, in normal cells at slightly acidic
pH FAK is in an autoinhibited state whereas in alkaline cancerous
cells, FAK activity and phosphorylation of Tyr397 increase leading
to cell proliferation and metastasis. The ability of FAK to respond to
changes in pH provides an additional mechanism of control of FAK
activity in normal versus cancerous cells. Ritt et al. proposed that
the mechanism behind the pH sensing ability of FAK relies on
protonation of H58 on the FERM's F1 lobe (Fig. 2A) (Ritt et al., 2013).
Protonated H58 likely forms a network of electrostatic interactions
with E466 on the kinase domain and therefore enhances the
autoinhibited conformation of FAK. In an independent study, based
on evidence from molecular dynamic studies, Choi et al. proposed
that deprotonation of His58 at higher pH, although not through
direct interaction, causes conformational changes in the linker re-
gion that expose the Y397 phosphorylation site (Choi et al., 2013).
Conversely, a slightly acidic pH appears to increase phosphor-
ylation of the FAT domain. Using a combination of biochemical andNMR structural analysis, Cable et al. showed that phosphorylation
of Y925 and Y1007 by Src is enhanced at pH 6e6.5, as compared
with pH 7.5. This effect might be linked to pH affecting the local
dynamics of the FAT structure. How an increase of Src-dependent
FAT phosphorylation under acidic pH conditions combines with
the opposing effect of decreased Y397 autophosphorylation and Src
recruitment to allow pH-dependent functions remains to be
determined (Cable et al., 2012).
9. Site-speciﬁc functions of FAK
Collectively, these data provide mechanistic explanations for
how intramolecular and intermolecular interactions determine the
site-speciﬁc functions of FAK. In the following we brieﬂy outline
how this frameworkmay explain FAK's different actions in different
subcellular environments. Sections 9.1e9.3 are illustrated in Fig. 4.
9.1. FAK in the cytoplasm
In the cytoplasm, without mechanisms for local enrichment, the
FAK concentration is too low for stable FAK dimerisation/clustering,
and FAK is expected to remain monomeric (Brami-Cherrier et al.,
2014). The FERM:FAT interaction in cis, although probably less
stable than in trans, may conceal the NLS on FERM and thus
counteract nuclear accumulation (Brami-Cherrier et al., 2014; Lim
et al., 2008; Ossovskaya et al., 2008). Because monomeric full-
length FAK cannot autophosphorylate Y397 in cis (Brami-Cherrier
et al., 2014), activation of kinase-dependent functions is inhibited
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200 kDa (FIP200) to the FERM and kinase domains of FAK further
inhibits residual kinase activity (Abbi et al., 2002). The exact
binding sites and mechanism for the inhibitory action of FIP200 are
unknown.
9.2. FAK at FAs
Clustering of integrins at sites of FAs induces clustering of paxillin
in the intracellular membrane-proximal space. Clustered paxillin
recruits FAK through the interaction between the LD motifs and the
FAT domain [other, paxillin-independent ways to recruit FAK also
exist (Cooley et al., 2000)]. This recruitment induces FAK dimers in
two ways: ﬁrstly, it locally enriches FAK, bringing the local FAK
concentration closer to the dimerisation Kd. Secondly, paxillin
binding to FAT reinforces the FERM:FAT interaction that stabilises the
dimers (Brami-Cherrier et al., 2014). FAK enrichment at FAs by
paxillin likely synergises with FAK enrichment through PI(4,5)P2,
which is locally synthesised at FAs (Goni et al., 2014). It is unclear
how PI(4,5)P2 binding to the KAKTLRK motif affects the FERM:FAT
interaction. Further stimulated by the presence of other co-factors
(such as cell surface receptor tails or local pH), this environment
promotes loosening and/or disruption of the inhibitory FERM:kinase
interaction, leading to Y397 phosphorylation within FAK clusters in
trans. pY397-FAK recruits and activates Src kinases, stimulating
phosphorylation of FAK and hence activation of kinase-dependent
functions of the Src-FAK complex. Within this activated Src:FAK
complex, FAK adopts a fully open conformation [(Cai et al., 2008;
Goni et al., 2014) and our unpublished data], maximally func-
tioning as a scaffold for assembly, phosphorylation and co-
localisation of ligands. It is unclear what triggers the conforma-
tional opening of FAT required for Y925 phosphorylation and Grb2
binding. It is possible that FAT opening is a probabilistic event,
gaining biological signiﬁcance in a clustered Src-FAK population
(Kadare et al., 2015). FAT opening and Grb2 binding disrupt the
interactionwith paxillin, whereas a fully deployed and disassembled
FAKmay be a better target for proteolytic cleavage and phosphatases.
These and other events may trigger FA disassembly and turnover
(discussed in greater detail in (Arold, 2011; Hall et al., 2011)).
The available mechanistic data may also explain why FAK
functions as a kinase-independent adaptor in early spreading ad-
hesions. In these structures paxillin binds to another molecule,
Nudel, and hence does not cluster and dimerise FAK (Shan et al.,
2009). The absence of FAK clusters and autophosphorylation may
explain why FAK functions as a kinase-independent adaptor in
early spreading adhesions, in conjunction with n-Wasp and Arp2/3
to control assembly and dynamics of the actin cytoskeleton (Serrels
et al., 2007).
9.3. FAK in the nucleus
Detachment of cells from the extracellular matrix can induce
anoikis, mediated by the tumour suppressor p53. This detachment-
triggered apoptosis is subverted in cancer cells, allowing metastatic
tumour cells to invade other tissues. It was proposed that FAK in-
hibits p53 following cell detachment (Fu et al., 2012; Golubovskaya
et al., 2008a; Lim et al., 2008). If focal adhesion contacts are lost,
FAK translocates into the nucleus, where it sequesters and in-
activates p53 and other pro-apoptotic effectors in a kinase-
independent manner, thereby promoting cell survival. To achieve
inactivation of p53, the FAK FERM domain functions as an adaptor
between p53 and the ubiquitin E3 ligase murine double minute-2
(Mdm2), to promote p53 ubiquitination and degradation
(Golubovskaya et al., 2005; Lim et al., 2008). In the nucleus, FAK
also inﬂuences DNA methylation through direct interaction withthe methyl-CpG-binding domain protein 2 (MBD2) (Luo et al.,
2009). MBD2 binds cytosine-methylated CpG islands, recruits his-
tone deacetylases and DNA methyltransferases, and thus acts as a
transcriptional repressor (Berger and Bird, 2005). The interaction
with FAK blocks MBD2 from recognising methylated CpG. It was
shown that this association enhances FAK's nuclear localisation and
allows it to regulate heterochromatin remodelling and myogenin
expression during muscle differentiation (Luo et al., 2009). Thus,
the controlled nuclear localisation allows FAK to logically link
membrane-proximal stimuli with gene expression and hence to
establish a link between adhesion, motility, survival and epigenetic
changes (Cance and Golubovskaya, 2008; Fu et al., 2012).
Nuclear localization is promoted by an NLS that includes the
K216AKTLRK basic cluster on the FERM domain (Lim et al., 2008)
and that is also required for the interaction between FERM and FAT.
Through yeast two-hybrid screening and cell lysate pull-down as-
says, it was shown that MBD2 binds directly to the FAT domain of
both FAK and Pyk2 (Luo et al., 2009). The MBD domain of MBD2 is
sufﬁcient for this interaction, but additional residues from the
glycineearginine rich (GR) region increase the afﬁnity. Based on the
available structural framework of FAK, we speculate that upon
binding to FAT, MBD2 disrupts the FAT:FERM interaction and re-
veals the NLS, promoting nuclear import (Brami-Cherrier et al.,
2014). In the absence of speciﬁc local enrichment, nuclear FAK is
expected to remain monomeric, a hypothesis compatible with its
function as a kinase-independent scaffold inhibiting pro-apoptotic
factors such as p53.
10. Pyk2 idiosyncrasies
In contrast to FAK, which is ubiquitous and highly expressed
during embryogenesis, Pyk2 appears at later developmental stages
and is abundant only in speciﬁc cell types, especially neurons
(Menegon et al., 1999). Nonetheless, Pyk2 is of high physiological
and biomedical relevance. In cell types where both FAK and Pyk2
are present, Pyk2 can synergise with FAK, or compensate for a loss
of FAK (resulting from knockout or speciﬁc inhibitors, for example),
and thus promote cancer cell survival and metastasis (Sulzmaier
et al., 2014; Weis et al., 2008). Indeed, Pyk2 expression is
increased in gliomas, hepatocellular carcinoma, lung, breast and
prostate cancers, and has been proposed as a therapeutic target for
invasive cancers (Allen et al., 2009; Lipinski and Loftus, 2010; Loftus
et al., 2009; Stanzione et al., 2001; Sun et al., 2008, 2011). Dereg-
ulation of Pyk2 in cell types where it is abundant, such as neurons,
osteoclasts and macrophages, has been linked to diseases associ-
ated with these cell types, such as neurodegeneration, osteoporosis
and inﬂammation (Gil-Henn et al., 2007; Lambert et al., 2013;
Okigaki et al., 2003). Importantly, the Pyk2 gene (PTK2B) was
recently discovered to be one of the genetic risk factors for Alz-
heimer's disease (Lambert et al., 2013).
10.1. Conserved mechanism despite differences?
FAK and Pyk2 share the same domain organization (Girault
et al., 1999; Lev et al., 1995b) (Fig. 5). Given the high sequence
identity of the FERM, kinase and FAT domains of these two proteins,
it is expected that fundamental mechanistic aspects of protein
activation are conserved. Indeed, Pyk2 can transiently self-
associate through interactions involving both its N-terminal and
C-terminal domains (Park et al., 2004). Self-association is required
for trans-autophosphorylation on Y402 (corresponding to FAK
Y397) (Bartos et al., 2010; Park et al., 2004). pY402 binds and ac-
tivates Src family kinases, which then phosphorylate other residues
in Pyk2 and associated proteins (Dikic et al., 1996; Park et al., 2004).
The Pyk2 FAT domain also binds to paxillin LD motifs (Lulo et al.,
Fig. 5. Pyk2 has adapted the domain organisation of FAK for calcium-sensing. (A) Sequence identities between Pyk2 and FAK are shown for individual regions. Reported Ca2þ/CaM
binding motifs of Pyk2 are shown in yellow (Kohno et al., 2008; Xie et al., 2008). (B) The structures of the isolated Pyk2 FERM (green; PDB 4EKU, lobes F1eF3 are indicated) and
kinase (cyan; PDB 3FZO) domains are positioned as in the FAK FERM-kinase fragment (PDB 2J0J). Although this FERM:kinase association has not yet been observed experimentally,
we speculate that Pyk2 also adopts such a FAK-like conformation, because the FAK FERM-kinase interface is conserved in Pyk2. The Pyk2 key residue F599 (blue), corresponding to
FAK Y596, is highlighted. Reported Ca2þ/CaM binding motifs are mapped onto the FERM and kinase domains (orange). (C) Complex formed between the Pyk2 FAT domain (magenta)
and paxillin LD4 motifs (PDB 3GM1) (Lulo et al., 2009).
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adhesions in most cell types. Moreover, Pyk2 has the unique ca-
pacity to sense calcium ions (Ca2þ). This capacity enables Pyk2 to
act as a central transducer of the Ca2þ signal in FA turnover
(Hashido et al., 2006) and allows it to execute speciﬁc functions
outside of FAs (Andreev et al., 1999). For example, Pyk2 activation in
neurons by Ca2þ promotes neurite outgrowth and is involved in
synaptic plasticity (Girault et al., 1999).
Pyk2 has evolved through FAK gene duplication in vertebrates
and subsequent specialisation (Corsi et al., 2006). How Pyk2 has
adapted the FAK scaffold to sense Ca2þ is unknown. Several path-
ways may contribute to Ca2þ-dependent trans-autophosphor-
ylation of Pyk2. Two groups reported that Pyk2 binds Ca2þ-bound
calmodulin (Ca2þ/CaM); however the proposed mechanisms differ
(Kohno et al., 2008; Xie et al., 2008). Kohno et al. reported that
Ca2þ/CaM binds to, and dimerises, the FERM domain, which is
necessary for Pyk2 trans-autophosphorylation (Kohno et al., 2008).
Conversely, Xie et al. located a Ca2þ/CaM binding site within the
Pyk2 kinase domain (Xie et al., 2008). Both groups used sequence
homology to known CaM binding motifs to identify, and muta-
tionally disrupt, their putative CaM binding site. However, in both
cases, the suggested binding site is mostly buried inside the FERM
or kinase domain structure, inaccessible to canonical Ca2þ/CaM
interactions (Fig. 5B).
More indirect and often cell-type speciﬁc mechanisms also
exist. In neurons Ca2þ/CaM has been reported to bind to the post-
synaptic density protein 95 (PSD-95), releasing an autoinhibitory
interaction and allowing PSD-95 to cluster and activate Pyk2
(Bartos et al., 2010). The PSD-95 SH3 domain binds to a proline-rich
region situated between the kinase and FAT domain of Pyk2(Seabold et al., 2003). PSD-95 forms oligomers, and Pyk2 dimer-
isation or clustering through Ca2þ/CaM:PSD-95 triggers Y402
autophosphorylation in trans. Increased Ca2þ levels also trigger
Pyk2 autophosphorylation through activation of protein kinase C
(PKC) (Lev et al., 1995a) or calmodulin-dependent kinase II (CaMKII)
(Ginnan and Singer, 2002; Guo et al., 2004; Zwick et al., 1999). In
PC12 cells, Ca2þ entry triggers both Pyk2 activation and cytonuclear
accumulation, and the Ca2þ-dependent Ser/Thr phosphatase cal-
cineurin is required for these effects (Faure et al., 2007). The role of
protein kinase A (PKA) and protein phosphatase 1(PP1) has also
been suggested (Battistone et al., 2014; Park et al., 2000; Rotfeld et
al., 2014) {Park, 2000 #806; Battistone, 2014 #808; Rotfeld, 2014
#807}. Pyk2 contains several putative (de)phosphorylation sites for
these kinases and phosphatases, mainly located in the kinase-FAT
linker (Oppermann et al., 2009) {Oppermann, 2009 #606}. Thus,
Pyk2 appears to be able to detect multiple signals triggered by Ca2þ.
However, the molecular basis for how Pyk2 translates changes in
cytoplasmic calcium levels into biological responses remains to be
established. Interestingly, the crystal structure of the isolated Pyk2
FERM domain (PDB accession nr. 4EKU) shows identical FERM:-
FERM dimers as observed and as demonstrated to be biologically
relevant to FAK (Brami-Cherrier et al., 2014) (Fig. 3B). We speculate
that Pyk2 has adapted the ligand-induced dimer-activation mech-
anism of FAK so that Ca2þ-dependent mechanisms stabilise a weak
FERM:FERM interaction for productive trans-autophosphorylation.
10.2. Nuclear Pyk2
Like FAK, Pyk2 is able to translocate to the nucleus (Faure et al.,
2007). Pyk2 accumulates in the nucleus following Ca2þ inﬂux
K.W. Walkiewicz et al. / Progress in Biophysics and Molecular Biology 119 (2015) 60e7168(Faure et al., 2007), suggesting a correlation between Ca2þ/CaM-
binding and nuclear localisation. This translocation involves
dephosphorylation of S778 by calcineurin, a Ca2þ/CaM activated
phosphatase, which appears to inactivate a nuclear export
sequence (Faure et al., 2013).
Like FAK, Pyk2 associates with MBD2 (Luo et al., 2009), and this
association correlates with a nuclear localisation of both proteins.
The physiological effects of the Pyk2:MBD2 association, especially
in neurons and other cell types where Pyk2 plays a central role,
remain unknown, although it has been suggested that the
Pyk2:MBD2 complex might regulate gene expression (Mei and
Xiong, 2010). Formation of such a complex may reduce MBD2
binding to methylated DNA and indirectly enhance gene expres-
sion. The atomic basis for the interaction between Pyk2 and MBD2
is unknown. Available data strongly suggest that MBD2 associates
in the same way with the FAT domains of either FAK or Pyk2 (Luo
et al., 2009). Indeed, the FAK and Pyk2 FAT domains share 57%
sequence identity, form the same 3D structure and bind paxillin LD
motifs in the same way (Fig. 5C) (Alam et al., 2014; Hoellerer et al.,
2003; Lulo et al., 2009; Vanarotti et al., 2014).
11. Targeted inhibition of FAK and Pyk2
Owing to their central role in linking adhesion, migration and
survival, FAK and Pyk2 constitute potential therapeutic targets.
Targeted small-molecule inhibitors for FAK produce encouraging
results in mousemodels, where they prevented growth, metastasis,
vascular permeability and angiogenesis of tumours (reviewed in
(Sulzmaier et al., 2014)). Of particular interest, these inhibitors also
sensitise cancer cells to chemotherapy, thus providing dual bene-
ﬁts. Currentlymost FAK inhibitors, and all those in clinical phase I/II
trials, are ATP-competitive kinase inhibitors (Sulzmaier et al., 2014).
Some compounds achieve enhanced speciﬁcity by stabilising a
particular helical conformation of the FAK kinase activation loop
‘DFG’ motif (Lietha and Eck, 2008; Roberts et al., 2008). However
developing highly speciﬁc ATP-competitive agents for FAK remains
challenging, and PPIIs would provide an attractive novel tool for
cancer therapy (Morelli et al., 2011). Several PPIIs were reported for
FAK that showed anti-tumour activity in xenograft mouse models,
and sensitised cancer cells to chemotherapy (Golubovskaya et al.,
2012, 2013, 2008b; Hochwald et al., 2009; Kurenova et al., 2014,
2009). The proposed targets of those compounds are Y397, the
reported p53 binding site on FERM, and the reported VEGFR-3
binding site on the FAT domain. These compounds, which were
identiﬁed through in silico docking studies, are currently only weak
inhibitors; they require high micromolar dosages and their selec-
tivity and precise mode of action remain to be completely
established.
Currently, the only Pyk2 inhibitors in preclinical trials are ATP-
competitive kinase inhibitors (Sulzmaier et al., 2014). For
function-speciﬁc anti-Pyk2 PPIIs, especially in diseases other than
cancer, a better evaluation of the biological role of Pyk2 is required
to assess the potential beneﬁts or risks of inhibition. For example it
is not known whether it is an increase or a decrease in Pyk2
function that contributes to an increased risk of Alzheimer's disease
(Kaufman et al., 2015; Xu et al., 2014).
12. Conclusions & remaining challenges
Despite recent advances in our mechanistic understanding of
FAK and Pyk2, several aspects of their complex structure-function
relationship remain elusive. For example, it is unclear how all
those ligands that require the KAKTLRK basic motif on FERM syn-
ergise or compete for this motif. In fact, the possibility that muta-
tions in the motif increase conformational dynamics of the F2 lobe,and thus allosterically block binding of ligands to different or
remote sites on F2, cannot be excluded. Substantial F2 destabili-
sation is expected to disrupt the F2-mediated autoinhibition be-
tween the FERM and kinase domain. Hence, controlled F2
destabilisation might also explain how FAK activation results from
c-Metepromoted phosphorylation of Y195 (Chen et al., 2011), or
PIAS-1emediated sumoylation of K152 (Kadare et al., 2003),
because both Y195 and K152 are buried inside the F2 fold.
It also remains to be determined how the 220 residueelong
kinase-FAT linker blocks phosphorylation in cis of Y397, although
this residue is located between the FERM and kinase domains. This
linker region presents the lowest sequence similarity between FAK
and Pyk2 (Fig. 5), and it remains to be determined how these
divergent sequences support the functional idiosyncrasies of both
homologues.
Additional structural data would be required to better under-
stand FAK's function in the nucleus, especially how FAK links p53
andMdm2, and how FAK and Pyk2 interact with MBD2, resulting in
changes in DNAmethylation patterns. Further mechanistic insights,
on an atomic level, would be needed to understand the role of these
molecules in mechanotransduction (Bae et al., 2014; Berk et al.,
1995). Finally, understanding the function of FAK and Pyk2 also
requires investigating the importance of noise, synergy and struc-
tural/functional heterogeneity within clustered FAK or Pyk2 pop-
ulations embedded in adhesomes or other complex structures
(Ladbury and Arold, 2012). Understanding such complex systems
on a molecular and holistic level might now be possible through
hybrid methods combining experimental and computational
methods with molecular imaging in cells or in cell-free systems
(Kanchanawong et al., 2010; Wilhelm et al., 2014; Zaidel-Bar et al.,
2007). A detailed knowledge of the complex structure-function
relationship of FAK and Pyk2 would enable precise targeting of
proteineprotein interactions by inhibitors, and might provide an
inspiration for novel biotechnological applications and tools.
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